Fig. 1: Humoral and cellular SARS-CoV-2 immunity in >80- and 20–53-year-old study participants vaccinated with the BNT162b2 vaccine. | Nature Microbiology

Fig. 1: Humoral and cellular SARS-CoV-2 immunity in >80- and 20–53-year-old study participants vaccinated with the BNT162b2 vaccine.

From: Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults

Fig. 1

a–c, SARS-CoV-2-spike-specific serum IgG antibody titres (a), serum titres of 100% virus neutralization (VNT 100) for SARS-CoV-2 wild type (B.1) or its delta variant (B.617.2) (b) and percentages of SARS-CoV-2-spike-specific CD4 T cells (c) were analyzed in 51 donors aged >80 years (blue symbols) and 46 donors aged 20–53 years (yellow symbols) before (day 0; a,c), 21 d after the first (a,c) and 14 d after the second BNT162b2 (Pfizer-Biontech) vaccination (day 35; a–c). Each symbol represents one donor. Horizontal lines indicate medians, dotted lines indicate the cut-off for antibody positivity at 35.2 BAU ml−1 (a) and 8 (reciprocal titre) for VNT (b). A cut-off value for determining reactive T cells could be considered at 0.01% as shown previously6 (c). P values determined by two-tailed Mann–Whitney test.

Source data

Back to article page